- Conditions
- Infections, Papillomavirus
- Interventions
- Data collection
- Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 9 Years to 25 Years · Female only
- Enrollment
- 1,516 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Wilmington, Delaware
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 229
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthmatic
- Interventions
- ccIIV4, IIV4
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 5 Years to 11 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Durham, North Carolina • Cincinnati, Ohio + 1 more
- Conditions
- HIV Infections, Sexually Transmitted Diseases
- Interventions
- Internet-based tailored prevention messages, Non-tailored messages
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 1,870 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Asthma
- Interventions
- Levalbuterol, Levalbuterol UDV TID, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- Up to 48 Months
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 46
- States / cities
- Little Rock, Arkansas • Cypress, California • Long Beach, California + 35 more
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
- Interventions
- Idelalisib, Rituximab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 6
- States / cities
- La Jolla, California • Stanford, California • New York, New York + 2 more
- Conditions
- Asthma
- Interventions
- Mometasone furoate/formoterol fumarate (MFF), Formoterol fumarate 12 μg pMDI (F12M), Formoterol fumarate 12 μg DPI (F12D), Placebo to F12D, Placebo to F12M/MFF
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 5 Years to 11 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 6
- States / cities
- Mobile, Alabama • Huntington Beach, California • Orange, California + 3 more
- Conditions
- Improvement in Immune Cell Function in Healthy Humans
- Interventions
- Aged garlic extract, AGE
- Dietary Supplement
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy
- Interventions
- ADX-097
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Hollywood, Florida • Lawrenceville, Georgia • Orangeburg, South Carolina
- Conditions
- Lymphoma, Large-Cell, Diffuse
- Interventions
- Rituximab, Etoposide, Carboplatine, Ifosfamide + Mesna, Cisplatine, Cytosine Arabinoside, Dexamethasone, Autologous Stem Cell Transplantation, BCNU, Cytarabine, Melphalan
- Drug · Procedure
- Lead sponsor
- Lymphoma Study Association
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 481 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Acalabrutinib, Rituximab
- Drug · Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 65 Years to 99 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 14
- States / cities
- Berkeley, California • La Jolla, California • Orange, California + 11 more
- Conditions
- Aging, Disease
- Interventions
- High Intensity Interval training
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 65 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Dermatitis Atopic
- Interventions
- Amlitelimab, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 67 more
- Conditions
- Elderly Immune System
- Interventions
- Flu Vaccine
- Biological
- Lead sponsor
- Health Sciences North Research Institute
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 393 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Myeloid Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Chronic Myelomonocytic Leukemia, Refractory Mixed Phenotype Acute Leukemia
- Interventions
- Decitabine, Laboratory Biomarker Analysis, Venetoclax
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Asthma
- Interventions
- Fluticasone Furoate, Fluticasone Propionate, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 5 Years to 11 Years
- Enrollment
- 597 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 37
- States / cities
- Little Rock, Arkansas • Costa Mesa, California • Huntington Beach, California + 33 more
- Conditions
- Asthma
- Interventions
- Fluticasone propionate 100mcg, Placebo, Vilanterol
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 5 Years to 11 Years
- Enrollment
- 463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 31 more
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Sarilumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Multiple Sclerosis
- Interventions
- mRNA-1195, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 8
- States / cities
- Boston, Massachusetts • Farmington Hills, Michigan • Ozark, Missouri + 5 more
- Conditions
- COVID-19
- Interventions
- Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir, Placebo for ritonavir
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 25
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Doral, Florida + 15 more
- Conditions
- Asthma
- Interventions
- Fevipiprant
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 6
- States / cities
- Minneapolis, Minnesota • Columbia, Missouri • Tulsa, Oklahoma + 3 more
- Conditions
- Diffuse Large B-Cell Lymphoma, Lymphoma, Diffuse Large-Cell, Diffuse Large-Cell Lymphoma, Lymphoma
- Interventions
- Bendamustine, Rituximab
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 7
- States / cities
- Boone, North Carolina • Chapel Hill, North Carolina • Concord, North Carolina + 4 more
- Conditions
- Healthy Volunteers
- Interventions
- Abrocitinib tablet, Abrocitinib Suspension F1, Abrocitinib Suspension F2, Abrocitinib Suspension F3, Abrocitinib Suspension F4, Abrocitinib Suspension F5, Abrocitinib Suspension F6, Famotidine
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Perennial Allergic Rhinitis
- Interventions
- GSP 301 NS, GSP 301 Placebo NS pH 3.7, GSP 301 Placebo NS pH 7.0
- Drug
- Lead sponsor
- Glenmark Specialty S.A.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 601 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 34
- States / cities
- Hot Springs, Arkansas • Encinitas, California • San Diego, California + 23 more
- Conditions
- Asthma
- Interventions
- BDA MDI (PT027) 160/180 μg, Pulmicort Respules 0.5 MG/ML Inhalation Suspension
- Drug
- Lead sponsor
- Bond Avillion 2 Development LP
- Industry
- Eligibility
- 4 Years to 8 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- Oklahoma City, Oklahoma • Boerne, Texas